BACKGROUND: Guidelines for the treatment of nonmetastatic inflammatory breast cancer (IBC) using trimodality therapy (TT) (chemotherapy, surgery, and radiotherapy) have remained largely unchanged since 2000. However, many patients with nonmetastatic IBC do not receive TT. It is unknown how patient-level (PL) and facility-level (FL) factors contribute to TT use. METHODS: Using the National Cancer Data Base, patients with nonmetastatic IBC who underwent locoregional treatment from 2003 through 2011 were identified. The authors correlated PL factors, including demographic and tumor characteristics, with TT use. An observed-to-expected ratio for the number of patients treated with TT was calculated for each hospital by adjusting for significant PL factors. Hierarchical mixed effects models were used to assess the percentage of variation in TT use attributable to PL and FL factors, respectively. RESULTS: Of the 542 hospitals examined, 55 (10.1%) and 24 (4.4%), respectively, were identified as significantly low and high outliers for TT use (P<.05). The percentage of the total variance in the use of TT attributable to the facility (11%) was nearly triple the variance attributable to the measured PL factors (3.4%). The nomogram generated from multivariate logistic regression of PL factors only allows a facility to assess TT use given their PL data. CONCLUSIONS: FL factors rather than PL factors appear to contribute disproportionately to the underuse of TT in patients with nonmetastatic IBC. To improve treatment guideline adherence for patients with nonmetastatic IBC, it is critical to identify the specific FL factors associated with TT underuse. More organized FL intervention is required to train physicians and to build multidisciplinary teams. Cancer 2017;123:2618-25. V C 2017 American Cancer Society.
INTRODUCTION
Inflammatory breast cancer (IBC) is a rare but highly aggressive form of invasive breast cancer. Although IBC comprises only approximately 2% of all breast cancers, population-based studies have suggested an increasing incidence. 1 IBC has a poor prognosis, with a median disease-free survival of < 2.5 years and a 5-year overall survival (OS) rate of 30% to 40%. 2 IBC treatment guidelines published by the National Comprehensive Cancer Network recommend neoadjuvant chemotherapy followed by modified radical mastectomy and postmastectomy radiotherapy to the chest wall and lymphatic draining (termed trimodality treatment [TT] ). 3 To the best of our knowledge, the recommendation of TT has remained unchanged since 2000. A multidisciplinary approach is crucial for the optimal management of patients with IBC. Using the National Cancer Data Base (NCDB), Rueth et al conducted a study to examine the trends of TT use, factors related to TT use, and its association with OS among women who underwent surgical treatment of nonmetastatic IBC. 4 They found that 5-year and 10-year OS rates were highest among patients who received TT compared with patients who received a different combination of treatments, and that variation in the management of IBC was substantial.
The evaluation of quality in cancer care delivery plays an essential role in modern medical practice. 5 Measuring adherence to guidelines and treatment pathways is one of the first steps in determining the quality and value of the medical care delivered. 6 Although it is evident that adherence to TT guidelines for the treatment of patients with nonmetastatic IBC will result in better patient outcomes, to the best of our knowledge there have been limited reports regarding variations in the management of this disease. In the current study, we aimed to examine TT use by facility-level (FL) factors and to evaluate the relative impact of these factors compared with patient-level (PL) factors on the use of TT. We further developed a quality measurement tool for individual hospitals, namely a nomogram adjusting for PL factors that can be used to evaluate adherence to the treatment guideline given their unique mix of patient and tumor characteristics.
MATERIALS AND METHODS

Data Source
The NCDB is a joint program of the American College of Surgeons Commission on Cancer (CoC) and the American Cancer Society and is used as a surveillance tool to assess patterns of care among patients with cancer. 7 The NCDB contains approximately 29 million records from the approximately 1450 CoC-approved hospitals across the United States. The NCDB includes approximately 70% of all new cancer diagnoses in the country annually. 8 The database collects PL data, including patient demographics, tumor characteristics, types of treatment administered, health insurance, and outcome variables and FL data, including the treating facility type and location. Each facility reporting cases to the NCDB is assigned to a cancer program (CP) by the CoC accreditation program based on the facility type, services provided, and cases accessioned, and then is classified as an academic/research hospital CP, a comprehensive community CP, a community hospital CP, or other specified type of CP. The other specified types of CPs include Veterans Affairs programs, pediatric programs, hospital-associated programs, and freestanding CPs. Details regarding the definitions can be found at the American College of Surgeons Web site (https://www.facs.org/qualityprograms/cancer/accredited/ about/categories.)
Study Cohort
Patients who underwent locoregional treatment of nonmetastatic IBC from 2003 to 2011 were identified. We included female patients who underwent surgical resection of any type (segmental mastectomy or mastectomy with or without axillary lymph node dissection) with any histologic breast cancer subtype and any lymph node status who had a clinical diagnosis of de novo IBC (ie, T4d [stage IIIB or IIIC disease according to the fifth, sixth, or seventh editions of the American Joint Committee on Cancer staging system] breast cancer). 9 Among a total of 7727 patients who otherwise met the aforementioned criteria regardless of the type of surgery, those who did not undergo surgical treatment (2190 patients; 28%) were excluded to reduce heterogeneity of the patient study cohort so that we could assess treatment guideline compliance among the patients who were in relatively good performance status and in principle should receive TT. Patients were excluded further if they had a prior cancer diagnosis or were diagnosed through autopsy or death certificate. Patients from hospitals that had treated <5 patients with IBC over the study period were excluded. Although patients may have received care for their IBC at >1 facility, the NCDB allows for the capture of different elements of the initial course of care (chemotherapy, surgery, or radiotherapy) regardless of where it was delivered. Therefore, we believe that our data captures such patients who had fragmentation of their initial IBC treatment.
Definition of TT
For the purposes of the current study, a patient was defined as having received TT if she underwent surgical treatment of nonmetastatic IBC, and received any type of chemotherapy and radiotherapy in the first treatment course at any facility.
Statistical Analysis
Univariate analyses were performed to evaluate the association between each PL or FL variable and TT, using the chi-square test for categorical variables and Student t tests/ for continuous variables. 10 The logistic regression model was used to assess the multivariate relationship between PL factors and the probability of receiving TT. 11 A logistic regression model was obtained by first including an initial set of candidate predictor variables with a P value < .05 in the univariate analysis. A stepwise elimination was performed using a P value of .05 for statistical significance to obtain a parsimonious model. Because the Charlson-Deyo Comorbidity Score was not collected until 2003, only those patients diagnosed with nonmetastatic IBC from 2003 through 2011 were included in the current analyses. The FL factors (facility type and facility location) were not included in the model-building procedure, but were forced into the final multivariate model.
We sought to ascertain the hospital rate of TT use after adjusting for PL factors to identify potentially modifiable FL treatment-related factors. We first developed a PL multivariable model for TT use that incorporated important PL variables, leaving the FL factors unadjusted in the model for post hoc comparison. This model was used to calculate the expected number of patients receiving TT for each hospital by summing the predicted probability of receiving TT for all patients. The observed Treatment Adherence in Nonmetastatic IBC/Lin et al
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July 15, 2017 number of patients receiving TT then was divided by the expected number of patients receiving TT (based on the PL factors) to create an observed-to-expected (O/E) ratio for each hospital. To evaluate the significance of the O/E ratio, the probability that a hospital treated equal to and greater than (O/E > 1) or equal to and less than (O/ E < 1) the observed number of patients receiving TT was determined on the basis of the binomial distribution B (n, k, and p). Herein, k denotes the actual number of patients receiving TT within the hospital, n denotes the total number of patients treated for nonmetastatic IBC in the hospital over the study period of 2003 through 2011 (ie, IBC patient volume of the hospital), and p denotes the modelderived expected probability of receiving TT. Hospitals with O/E ratios significantly > 1 were designated as significantly high outliers. Similarly, hospitals with O/E ratios significantly < 1 were designated as significantly low outliers.
12 FL factors were descriptively compared by high or low outlier status.
To assess each hospital's adherence to TT guidelines for patients with nonmetastatic IBC, we constructed a nomogram using the multivariate logistic regression model with PL factors only and internally validated for model discrimination and calibration by bootstrapping with 200 resamples. Model discrimination first was quantified using the concordance index to measure the predictive accuracy of the model. After quantifying the model discrimination, the model calibration was graphically assessed using a calibration plot.
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To account for the fact that patients were nested within the hospitals in which they received treatment, and to estimate the percentage of variation of TT use attributable to FL and PL covariates, 13, 14 we applied hierarchical mixed effects models to the use of TT. The unit of analysis in the logistic regression was the patient. This multilevel logistic regression model assumes a FL random effect, which explicitly considers the intradependencies among patients treated in the same facility. The variance of the random intercept describes the heterogeneity in TT rates among hospitals after accounting for PL covariates. To measure the contributions of the FL factors and PL factors on TT use, we used the threshold method to estimate the percentage of outcome variance attributable to FL or PL effects in accordance with published methods. 15, 16 According to the results of the model with PL factors only, we included age at diagnosis, year of diagnosis, median income, and pathologic lymph node stage as fixed covariates in the mixed effects models.
Patients with missing data regarding any of the outcome variables or above covariates were excluded from the analyses reported assuming missing is completely at random.
SAS statistical software (version 9.2; SAS Institute Inc, Cary, NC) and S-Plus statistical software (version 8.04, TIBCO Software Inc., Palo Alto, Calif.) were used to perform the computations for all analyses.
RESULTS
PL Factors Associated With Use of TT
A total of 5537 patients who met the study criteria were identified. Table 1 shows the study cohort's distributions with regard to PL and FL variables. The use of TT fluctuated annually from 2003 to 2011 (range, 67.3%-75.7%). The final multivariate model with PL factors indicates that the use of TT was more likely for patients who were younger, had a higher income, or had a pathologic N1 tumor (all P<.05) ( Table 2 ). Based on insurance type, the use of TT was found to be lowest among Medicare patients; however, insurance type was not found to be statistically significant in the final multivariable model.
Comparison of TT by FL Factors
There were a total of 542 hospitals included in the study cohort (155 academic/research hospital CPs, 335 comprehensive community CPs, 46 community hospital CPs, and 6 other specified hospitals). The volumes of patients with IBC over the study period of the academic/research hospital CPs and comprehensive community CPs (median of 10 patients [interquartile range (IQR), 7-14 patients] and 8 patients [IQR, 6-12 patients], respectively) were higher than those of the community CPs and other specified hospitals (median of 5 patients [IQR, 5-6 patients] and 5 patients [IQR, 5-8 patients], respectively). Figure 1 Top shows the PL risk-adjusted O/E ratio of patients who received TT. The circle size is proportional to the volume of patients with IBC for each individual hospital. The red circles are the hospitals with O/E ratios significantly < 1, whereas the blue circles are hospitals with O/E ratios significantly > 1. Of the 542 hospitals included in the current study, 55 (10.1%) were identified as significantly low outliers and 24 (4.4%) were identified as significantly high outliers for the use of TT (P<.05) (Fig. 1 Top) . The distribution of the high or low outliers by facility type is shown in Figure 1 Bottom. Specifically, 24 of 155 academic/research hospital CPs (15.5%), 29 of 335 comprehensive community CPs (8.7%), 1 of 46 community CPs (2.2%), and 1 of 6 other specified hospitals (16.7%) were low outliers. Conversely, 7 of 155 academic/research hospital CPs (4.5%), 17 of 335 comprehensive community CPs (5.1%), none of 46 community CPs Original Article (0%), and none of 6 other specified hospitals (0%) were high outliers. All 24 hospitals designated as high outliers were academic/research hospital CPs and comprehensive community CPs.
The use of TT was not found to be statistically significantly associated with the type of facility (P 5 .33) ( Table 2 ) after adjusting for the significant PL factors and facility location. Instead, facility location was found to be significantly associated with the use of TT (P<.0001) ( Table 2) . Specifically, 34 of 198 hospitals in the South (17.2%) and 4 of 139 hospitals in the Midwest (2.9%) were low outliers. In contrast, 13 of 139 hospitals in the Midwest (9.4%) and only 5 of 198 hospitals in the South (2.5%) were high outliers.
Multilevel Analyses to Analyze Variance Among Hospitals in the Use of TT
The residual interclass coefficient was calculated from the multilevel logistic regression model with the fixed-effect PL variables including age at diagnosis, year of diagnosis, income, and pathologic lymph node classification, assuming a FL random effect. The percentage of variance attributable to FL factors was 11%, which was nearly triple the variance attributable to the measured PL factors (3.4%).
Quality Evaluation Tool for Individual Hospitals
We constructed a nomogram for determining the expected rate of TT use for a given hospital using only the PL covariates in the multivariate logistic regression model (see Supporting Information Fig. 1) . The nomogram has a bootstrap-corrected concordance index of 0.58. The calibration plot demonstrated that the model fitted the data reasonably well. The expected TT rate per hospital was adjusted for patient characteristics, and therefore such a rate is comparable even though patient characteristics may be different between hospitals. 17 which recommended a multidisciplinary approach that included primary systemic chemotherapy, surgery, and radiotherapy in the treatment plan. Rueth et al demonstrated in a similar NCDB cohort that patients with nonmetastatic IBC who received TT had the best survival rates when compared with patients who received less comprehensive treatment regimens. 4 However, the use of TT varied widely across hospitals, and an average 30% of patients with nonmetastatic IBC did not receive optimal care according to the current practice guidelines.
Patients with nonmetastatic IBC for whom TT was omitted were predominantly aged >70 years, had lower income, or had an N0 tumor. However, the variability in TT adherence after adjusting for PL factors still was found to be substantial. FL, rather than PL, factors appear to contribute disproportionately to the underuse of TT to treat patients with nonmetastatic IBC.
Although comprehensive community CPs represented the majority of high outliers of TT use, and none of the community or other specified hospitals was identified as a high outlier, the facility type was not found to be significantly associated with TT in the multivariable model. The reason for this insignificant association most likely is due to a high variation in TT use among comprehensive community CPs (median, 76% [range, 0%-100%]) and among academic/research hospital CPs (median, 71% [range, 14%-100%]). As indicated in the data, some academic hospital CPs treated 100% of their patients who were diagnosed with nonmetastatic IBC with TT. In contrast, 1 academic hospital used TT to treat only 14% of their patients with nonmetastatic IBC. None or fewer of the community CPs and other specified hospitals were identified as statistically significantly high or low outliers We also found that hospitals located in the Midwest had the highest overall rate of TT use (77.2%), whereas those located in the South had the lowest rate (66.5%). Longer travel distances were not consistently observed for patients in the South compared with those in the Midwest, but a higher percentage of patients seen in the facilities located in the Midwest had an income that was $46,000 compared with patients seen in the facilities in the South (data not shown). This may explain in part the differences in the TT rates observed between the 2 areas. However, the reasons underlying these geographic differences likely are multifactorial, and are unclear without more information with which to characterize physicianlevel and hospital-level practices.
We constructed a nomogram that adjusts for PL factors to predict TT use for each hospital, so that one can assess the quality of care for patients with nonmetastatic IBC within each hospital and compare the adherence to treatment guidelines across the different hospitals. This quality assessment metric may increase the transparency of facility adherence to treatment guidelines, and help patients to identify a facility that provides TT for this rare disease. By identifying facilities with underuse of TT using the nomogram, organized interventions at the FL can be implemented to train physicians and build multidisciplinary teams to improve patient care for those with this rare disease.
The current study has limitations. First, the NCDB provides retrospective observational data, and a small percentage of the patients represented in the database had missing treatment data. Thus, we excluded these individuals from the analysis cohort. However, the missing treatment data were unlikely missing at random, which may indicate even greater variability in the practice of care within the broader community. Second, the NCDB only collected 2 FL factors, and did not include any physician-level data such as the decade in which the physician graduated from medical school, the specific medical degree, training location, and board certification. Combining the NCDB with other databases with detailed FL data and physician-level data, if possible, most likely would help researchers to further explore factors affecting the use of TT in patients with IBC. 18 Finally, the bootstrap-corrected concordance index of the multivariate model with the PL factors was only 0.58, indicating a merely better-than-random prediction of TT use by the model. Combining the NCDB with other databases with detailed FL data and physician-level data, if possible, most likely would improve the predictive ability of the model. Because IBC is rare and many hospitals only treat a few cases each year, it would be better to put in place quality management programs that result in 100% case review of patients with IBC with clear documentation of the reasons for treatment that is not in concordance with guidelines.
We found that the percentage of the total variance in the use of TT attributable to the facility (11%) was nearly triple the variance attributable to the measured PL factors (3.4%). These findings suggest that FL factors contributed to the decision to use TT more than PL factors. Therefore, to improve clinical outcomes for patients with nonmetastatic IBC, it is critical to identify what additional FL factors may impact the use of TT, in addition to the facility location and type.
To the best of our knowledge, the current study is among the first to evaluate variations in the use of TT to treat patients with stage III IBC based on the NCDB after adjusting for patient characteristics. The results of the current study demonstrated that FL rather than PL factors contributed disproportionately to the underuse of TT. Among academic/research hospital CPs and comprehensive community CPs, significant variability exists with regard to the treatment of patients with nonmetastatic IBC. TT should be delivered by a multidisciplinary team that consists of a breast surgeon and medical and radiation oncologists. Due to the rarity of IBC, it is critical to provide more education for physicians and to increase public awareness regarding its diagnosis and management. To improve the quality of care, and thereby increase the OS for patients with IBC, organized intervention at the FL is required to train physicians and build multidisciplinary teams. 
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